



Vivendy Therapeutics Ltd. achieves a total of CHF 32 million in series A financing round after second closing

Basel, Amsterdam and Munich, June 18th, 2008 – Vivendy Therapeutics Ltd, today announced the second closing of its series A financing round. Aescap Venture is joining the existing investor base consisting of BioMedInvest, LSP Life Science Partners and TVM Capital. The series A round totals CHF 32 million. Vivendy Therapeutics is now optimally funded to fastly drive the development of its lead product - a new therapy against *Morbus Morquio* - until market introduction.

Vivendy Therapeutics Ltd. is a pharmaceutical company developing an enzyme replacement therapy (ERT) for *Morbus Morquio* (Mucopolysaccharidosis (MPS) IVA), a rare, inherited, lysosomal storage disease. This disease is caused through the deficient activity of an enzyme (N-acetylgalactosamine-6-sulfatase (GALNS)) leading to a wide range of serious clinical consequences. Today, there is no therapy for MPS IVA in place; therefore the development of *Morbus Morquio* ERT addresses a serious unmet medical need.

Dr. Domenico (Dinko) Valerio, General Partner at Aescap Venture and founder and former CEO of Crucell NV will join the Vivendy Board of Directors. He stated: "It is very exciting to be part of a company with a product that has such a clear and fast development path towards registration. We are committed to help further accelerate the development of the *Morbus Morquio* therapy . I am convinced that Vivendy's approach of using a genetically modified enzyme rather than the native enzyme is especially useful and, moreover, necessary to effectively treat *Morbus Morquio* patients."

About Vivendy Therapeutics Ltd.

Vivendy Therapeutics was founded in March 2006, as a spin-off of Inotech Biotechnologies AG.

The company's mission is the development of an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis - MPS IVA), a rare lysosomal storage disease, based on a gene deficiency with an incidence of 1 to 200 000 live births. MPS IVA represents 5% of the lysosomal storage disorders (LSDs). More information at www.vivendy.ch

About Aescap Venture Management

Aescap Venture Management BV, is a venture capital firm focusing on the creation and growth of European (bio)medical companies. Through early and active involvement in the companies, Aescap Venture will achieve an accelerated development of its portfolio companies and their products. Aescap Venture currently has € 103 M under management. From its first fund, Aescap Venture invested in eight biomedical companies and led six investment rounds. The company was founded by Michiel de Haan, founder and former managing partner of Atlas Venture and Dr Dinko Valerio, founder and former CEO of Crucell, a Euronext/NASDAQ-listed biotechnology company. Other partners are Patrick Krol, an entrepreneur and expert in life science marketing and business development, and Kreske Nickelsen, a previous director of life sciences at 3i. For more information please visit: www.aescap.com.

About BioMedInvest AG I

BioMedInvest is a leading independent European venture capital firm, providing private equity and mezzanine financing to early- to mid-stage healthcare and life-science companies. Since 2003, BioMedInvest has invested in more than 20 highly innovative enterprises four of which have already successfully completed their IPO (Arpida AG, Santhera Pharmaceuticals AG) or have been acquired by leading companies in the industry (GlycArt Biotechnology AG) or by strategic investors (Thommen Medical AG). With more than CHF 210 million in capital under management and a strong team of experienced specialists with broad expertise and extensive scientific and financial networks, BioMedInvest has established itself as one of the leading early-stage healthcare investors in Europe. For additional information please visit: www.biomedvc.com

About LSP Life Sciences Partners

LSP (Life Sciences Partners) is a leading independent European venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With EUR 400 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors. Further information on Life Science Partners is available at www.lspvc.com

About TVM Capital

The TVM Capital Life Science Practice is one of the largest investors in venture and growth deals in biotechnology and pharmaceuticals in Europe, with a strong presence and a substantial team in the US and a growing presence in Asia through our network of venture partners and advisors. The Life Science team builds on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and almost 40 IPOs from our biotechnology and pharmaceutical portfolio of companies. 20 years of track record of successful investing and value creation in traditional early and late-stage venture as well as venture growth and growth capital make the TVM Capital Life Science Practice a unique partner for the needs of the pharmaceutical industry. For more information please visit: www.tvm-capital.com

Contact address:

Dr. Roland Toder, CEO
Vivendy Therapeutics Ltd.
Peter Merian Str. 45

CH-4052 Basel
Switzerland
T: +41 61 271 8780
E: toder@vivendy.ch
www.vivendy.ch

Disclaimer

This press release does not constitute or form part, or all, of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution from the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Vivendy, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Vivendy disclaims any obligation to update these forward-looking statements to reflect future events or developments.